Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Onconova, SymBio Complete License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Onconova, SymBio Complete License Agreement

Onconova Therapeutics and SymBio Pharmaceuticals will collaborate to develop and commercialize rigosertib in Japan and Korea.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Onconova Therapeutics and SymBio Pharmaceuticals will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting Phase III trials with rigosertib for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors. The FDA has granted orphan drug designation for the use of rigosertib in MDS, and a Special Protocol Assessment (SPA) for the Phase III trial design.

SymBio has an exclusive license to develop and commercialize rigosertib in Japan and Korea. Onconova will receive an undisclosed upfront payment and development milestones, as well as sales milestone payments and royalties. The two companies will enter into an agreement for the supply of clinical and commercial product.

“This is the first commercial transaction for our lead product rigosertib, and we are delighted that SymBio is our partner in Japan and Korea,” said Dr. Ramesh Kumar, president and chief executive officer of Onconova. “The broad reach of rigosertib across blood cancers as well as solid tumors, and the ability to address previously intractable indications with single agent and combination therapies, will provide multiple opportunities to serve the unmet medical needs of patients worldwide.”

In addition to the intravenous product development, an oral formulation of rigosertib is being developed for first line MDS and other indications.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters